
GenVivo GenVivo is a private, clinical-stage company, with a patented, off-the-shelf vector platform that fights cancer by activating the patient’s own immune system targeting the breadth of the patient’s own tumor antigens. GenVivo’s proprietary platform technology is a unique RNA vector delivered intravenously (or intratumorally) with capacity to deliver a combination of payloads engineered to act synergistically at the tumor site. GEN2, GenVivo’s lead clinical candidate, is now in a US Phase 1/2 clinical trial (NCT06391918). GEN2 is designed to stimulate the immune system against all patient-specific tumor antigens—thereby creating a personalizing anti-tumor effect without the time delay and expense associated with some cancer vaccines, which require biopsies and sequencing, and are limited in the number of antigens delivered. Beyond GEN2, our pipeline is focused on key areas of cancer immunotherapy: GEN-1013 (vector encoding for IL-12), in vivo CAR-T and targeted vectors. Therapeutic Developer

GenVivo

GenVivo is a private, clinical-stage company, with a patented, off-the-shelf vector platform that fights cancer by activating the patient’s own immune system targeting the breadth of the patient’s own tumor antigens. GenVivo’s proprietary platform technology is a unique RNA vector delivered intravenously (or intratumorally) with capacity to deliver a combination of payloads engineered to act synergistically at the tumor site. GEN2, GenVivo’s lead clinical candidate, is now in a US Phase 1/2 clinical trial (NCT06391918). GEN2 is designed to stimulate the immune system against all patient-specific tumor antigens—thereby creating a personalizing anti-tumor effect without the time delay and expense associated with some cancer vaccines, which require biopsies and sequencing, and are limited in the number of antigens delivered. Beyond GEN2, our pipeline is focused on key areas of cancer immunotherapy: GEN-1013 (vector encoding for IL-12), in vivo CAR-T and targeted vectors.

Therapeutic Developer